Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) announced several significant developments in its SEC Form 8-K filing dated February 21, 2025, including the termination of a long‐standing license agreement and the release of its fourth quarter and full year 2024 financial results.
On February 21, 2025, a wholly owned subsidiary of Kiniksa notified MedImmune Limited of its decision to terminate the MedImmune License Agreement for the development of mavrilimumab. Originally entered into on December 21, 2017 (as amended), the agreement provided MedImmune with an exclusive, sublicensable license to intellectual property rights for mavrilimumab. Kiniksa exercised its right to terminate the agreement for convenience, with the termination set to become effective on May 22, 2025. The decision to end the relationship reflects Kiniksa’s broader strategic reprioritization of its development portfolio.
Additionally, Kiniksa provided updates on its clinical pipeline. The company is set to initiate a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected later in the year 2026. KPL-387, a fully human immunoglobulin G2 monoclonal antibody targeting IL-1R1, is being developed with a target profile that could support monthly subcutaneous dosing. In parallel, Kiniksa is advancing KPL-1161 toward clinical development as an Fc-modified IgG2 antibody with a target for quarterly dosing. In a strategic move to streamline its portfolio, Kiniksa is discontinuing its Phase 2b clinical trial of abiprubart in Sjögren’s Disease. The company has already incurred approximately $19 million in expenses for the trial and anticipates recording an additional $14 million to $17 million in costs related largely to contract termination expenses.
Kiniksa’s current operating plan is expected to remain cash flow positive on an annual basis. The company plans to provide further details during a conference call and webcast scheduled for 8:30 a.m. Eastern Time on February 25, 2025.
This series of strategic updates underscores Kiniksa’s ongoing efforts to streamline its development programs and focus on indications with significant unmet medical needs, particularly in the cardiovascular space.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Kiniksa Pharmaceuticals’s 8K filing here.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Further Reading
- Five stocks we like better than Kiniksa Pharmaceuticals
- Investing in Commodities: What Are They? How to Invest in Them
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- The How And Why of Investing in Oil Stocks
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- Business Services Stocks Investing
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
